Burak Zeybek1, Yu-Li Lin2, Yong-Fang Kuo2, Ana M Rodriguez1. 1. Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston, TX. 2. Department of Preventive Medicine and Community Health, The University of Texas Medical Branch at Galveston, TX.
Abstract
OBJECTIVE: The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. MATERIALS AND METHODS: We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. RESULTS: A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p < .0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95% CI = 0.49-0.70), whereas it was 0.65 (95% CI = 0.49-0.85) and 0.67 (95% CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. CONCLUSIONS: Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.
OBJECTIVE: The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. MATERIALS AND METHODS: We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. RESULTS: A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p < .0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95% CI = 0.49-0.70), whereas it was 0.65 (95% CI = 0.49-0.85) and 0.67 (95% CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. CONCLUSIONS: Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.
Authors: Robine Donken; Mirjam J Knol; Johannes A Bogaards; Fiona R M van der Klis; Chris J L M Meijer; Hester E de Melker Journal: J Infect Date: 2015-02-21 Impact factor: 6.072
Authors: Gui Liu; Susan Hariri; Heather Bradley; Sami L Gottlieb; Jami S Leichliter; Lauri E Markowitz Journal: Sex Transm Dis Date: 2015-01 Impact factor: 2.830
Authors: Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt Journal: J Natl Cancer Inst Date: 2010-02-05 Impact factor: 13.506
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Ana M Rodriguez; Mehmet R Asoglu; Muhammet Erdal Sak; Alai Tan; Mostafa A Borahay; Gokhan S Kilic Journal: Eur J Obstet Gynecol Reprod Biol Date: 2015-11-28 Impact factor: 2.831
Authors: Elissa Meites; Rachel L Winer; Michael E Newcomb; Pamina M Gorbach; Troy D Querec; Jessica Rudd; Tom Collins; John Lin; Janell Moore; Thomas Remble; Fred Swanson; Justin Franz; Robert K Bolan; Matthew R Golden; Brian Mustanski; Richard A Crosby; Elizabeth R Unger; Lauri E Markowitz Journal: J Infect Dis Date: 2020-11-13 Impact factor: 5.226
Authors: Julia Ml Brotherton; Alison Budd; Christopher Rompotis; Natasha Bartlett; Michael J Malloy; Rachael L Andersen; Kim Ar Coulter; Peter W Couvee; Nerida Steel; Gail H Ward; Marion Saville Journal: Papillomavirus Res Date: 2019-07-15